TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Patient Oriented Discharge Summary Impact Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or over~* Able and willing to provide informed consent or have a substitute decision maker that can provide consent and agree to answer follow up as the patient's caregiver~* Admitted to hospital with either congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), Stroke, Pneumonia, Hip Fracture, Knee Replacement or Hip Replacement~* Being discharged home or to a retirement home~* Have a Telephone for post-discharge follow-up~Exclusion Criteria:~* Patients who have already received the PODS in the past~* Being discharged to nursing home, long-term care facility, rehabilitation or other hospital.~* Unable to communicate due to cognitive impairment or language barrier with no caregiver or interpreter available~* Palliative patient with life expectancy \<= 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PODS intervention (Type: EXPERIMENTAL): The PODS intervention is administered during the discharge process which includes discharge teaching. In the acute settings, discharge teaching is provided by a nurse navigator, resident physician, or other members of the care team. In the rehabilitation setting, discharge teaching is provided by a multi-disciplinary team. PODS is used as a useful add-on to the usual discharge teaching process. The PODS form used during the study will be a fillable pdf. Members of the healthcare team will fill it out electronically, then print it out and give the paper to the patient. After the discharge teaching is finished, patients take the completed PODS home with them as a post-discharge reference and guide.
- Usual Care (Type: NO_INTERVENTION): Patients randomized to this arm will receive usual discharge care. At UHN, this involves receiving a discharge summary with information pertaining to hospital course including investigations performed and medications used, as well as follow-up care suggested. It is intended to be, unlike PODS, a document for the primary care physician seeing the patient after discharge to refer to. As to discharge instructions provided for the patient, there is no standard procedure and sometimes follow-up instructions are included for the patient. Patient education may or may not be provided to the patient verbally by their nurse, resident, physician, or pharmacist. Moreover, follow-up with the primary care physician may be set up prior to or following discharge with the nurse navigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: High-Sensitivity Troponin T and Coronary Computed Tomography Angiography for Rapid Diagnosis of Emergency Chest Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chest pain consistent with possible acute coronary syndrome.~* Age \> 18 years.~* Informed consent.~Exclusion Criteria:~* Previous history of coronary artery disease.~* Electrocardiogram diagnostic or suggestive of myocardial ischemia.~* Condition other than coronary artery disease as cause of an imbalance between myocardial oxygen supply and/or demand (eg. anemia, fever, arrhythmias).~* Chronic kidney disease (GFR \<30 mL/min/1,73 m2).~* Iodine contrast allergy.~* Incapability to perform treadmill stress test.~* Barthel activity of daily living scale index \< 100.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Fast strategy (Type: EXPERIMENTAL): High sensitivity cardiac troponin T followed by computed coronary tomography angiography
- Standard of care strategy (Type: ACTIVE_COMPARATOR): Standard of care strategy based on serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patency of a Prototype Large Plastic Biliary Stent in the Palliation of Malignant Distal Biliary Strictures.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria:~1. ≥ 18 and ≤ 85 years of age~2. Malignant biliary obstruction, known or suspected~3. Increased bilirubin or jaundice or history thereof~4. Duct stricture (obstruction) ≥ 1 cm distal to the biliary hilum (bifurcation of the common hepatic duct into the right and left hepatic ducts)~5. Not an operative candidate~Exclusion Criteria:~1. Unable to obtain consent~2. Unable to tolerate endoscopic procedure~3. Suspected non-malignant bile duct stricture~4. Candidate for potentially curative surgical intervention~5. Previous SEMS~6. Previous bile duct surgery~7. Diffuse liver metastasis~8. Peritoneal metastasis by CT~9. Presence of ascites~10. Duodenal obstruction preventing passage of the duodenoscope to the level of the papilla~11. Failure to cannulate bile duct during ERCP~12. Karnofsky performance score \< 40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pancreatic Cancer Patients (Type: EXPERIMENTAL): A large plastic biliary stent was placed in the bile duct.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ages 10 years old and above~2. Patients who are newly diagnosed with high-risk acute lymphoblastic leukemia~3. Patients who have started or will start an induction chemotherapy regimen containing steroid and asparaginase~4. Patients (if over 18 years of age) or parent/guardian (if the patient is under 18 years of age) must be fluent in reading and speaking English~5. Parent or guardian living in the home with the participant who also receives training on diabetes, CGM, HCL therapy, and the safety protocols~Exclusion Criteria:~1. Preexisting diabetes~2. Severe psychiatric disease or developmental delays, that might interfere with ability to provide informed consent~3. Active skin condition that would affect sensor placement~4. Any other medical condition which in the opinion of the investigators impairs the person's ability to safely participate in the trial, including but limited to:~   1. Significant chronic kidney disease (eGFR \<60) or requiring hemodialysis~  2. Significant liver disease~  3. History of adrenal insufficiency~  4. History of abnormal TSH consistent with hypothyroidism or hyperthyroidism that is not appropriately treated~  5. History of thyroid cancer~5. Use of intravenous or oral acetaminophen more than 60 mg/kg/day (maximum 4000 mg/day)

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- Hybrid Closed-Loop Insulin System During Chemo with Steroid and Asparaginase (Type: EXPERIMENTAL): Subjects will receive insulin via hybrid closed-loop insulin delivery system during the chemotherapy phases that contains steroid and asparaginase. This treatment will be initiated within 4 days of starting induction chemotherapy treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Collaborative Care for Opioid Dependence And Pain Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic pain for at least 6 months~* Receiving daily opioid treatment~Exclusion Criteria:~* Not speaking English~* Significant psychiatric impairment including severe cognitive impairment, suicidality, schizophrenia, or bipolar disorder~* Known life expectancy of less than 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention Arm (Type: EXPERIMENTAL): Patients will receive the telecare intervention.
- Usual Care Arm (Type: NO_INTERVENTION): Patients will receive usual care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Child Health Initiative for Lifelong Eating and Exercise (CHILE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 3 years of age of beginning of intervention for each cohort (2)~* enrolled in participating Head Start~* informed consent signed by parent or legal guardian~Exclusion Criteria:~* 4 years of age or more at beginning of intervention for each cohort (2)~* not enrolled in a participating Head Start~* informed consent not provided

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 5 Years
- Healthy Volunteers: t

Study Arms:
- intervention 1 (Type: EXPERIMENTAL): This transcommunity study has one intervention and one control group. The intervention, described elsewhere has 6 components--classroom curriculum, family component,grocery store component, health care provider component, training for Head Start food service workers,and training for Head Start teachers/aides.
- control 2 (Type: NO_INTERVENTION): measurement only control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current or ex-smoker with at least a 10-year pack history~* COPD, defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \< 70% and FEV1% predicted \< 80%~* 25-hydroxy vitamin D3 (25\[OH\]D3) level less than 20 ng/mL prior to study initiation~* Willingness to comply with study guidelines~* Willingness to avoid alternative/additional vitamin D3 supplementation for the duration of the trial~* Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~Exclusion Criteria:~* Personal history of lung cancer or head and neck cancer~* History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, or tropical sprue)~* History of known thyroid disease~* History of known sarcoid disease~* History of known abnormalities in calcium metabolism~* Hypercalcemia (serum calcium in excess of laboratory upper limit normal \[ULN\])~* Self-reported consumption of more than 4 alcoholic drinks per day~* Use of anti-seizure medications phenobarbital or phenytoin, which can disrupt vitamin D metabolism~* History of known renal dysfunction~* History of known nephrolithiasis (kidney stones)~* Current use of supplemental oxygen~* Inability to exercise due to musculoskeletal issue, osteoarthritis or underlying cardiac disease~* Current participation in a cancer intervention prevention study, except for smoking cessation~* Any condition which in the Investigator's opinion deems the subject an unsuitable candidate to receive study drug~* Inability to swallow pills~* Vitamin D supplementation \> 2,000 IU/day of vitamin D within 30 days prior to enrollment~* Positive Pregnancy Test

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control arm (multivitamin, placebo) (Type: ACTIVE_COMPARATOR): Patients receive a placebo and multivitamin orally each day for 52 weeks.
- Supplementation arm (multivitamin, cholecalciferol) (Type: EXPERIMENTAL): Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Medical Assistance for the Procreation and Risk of Thrombosis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All women undergoing ovarian stimulation in order to receive in vitro fertilization~Exclusion Criteria:~* Age\<18 years~* Women refusing to particpate in the study~* No health coverage~* Women under guardianship~* Women receiving therapeutic doses of anticoagulation

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Women undergoing ART (Type: None): Observation of the incidence of venous and arterial thrombosis following ovarian stimulation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active pouchitis (defined as having a PDAI score \> 7) after IPAA for UC, despite at least 14 days of antibiotic therapy. Active pouchitis must be confirmed by endoscopy and histology within 4 weeks of study entry~* Able to give informed consent~* Able and willing to comply with all study procedures~Exclusion Criteria:~* Patients previously treated with infliximab or any investigational immunosuppressant/ immunomodulator for pouchitis~* Patients undergoing chemotherapy for the treatment of cancer~* Presence of other inflammatory diseases of the pouch: Crohn's disease, Cuffitis, active specific infection of the pouch: (e.g., CMV, C. difficile)~* History of non-inflammatory disease of the pouch: decreased pouch compliance, irritable pouch syndrome, afferent or efferent limb obstruction, stricture of pouch~* Ileal pouch patients with familial adenomatous polyposis~* History of other diarrheal illnesses: lactose intolerance, celiac disease, small bowel bacterial overgrowth~* Primary Sclerosing Cholangitis with or without liver transplant~* Uncontrolled systemic disease~* Needing oral or topical 5-ASA, cholestyramine, steroids or immunomodulators~* Other major physical or major psychiatric illness within the last 6 months that in the opinion of the investigator would affect the patient's ability to complete the trial~* Women who are pregnant, breast feeding, or planning to become pregnant during the study~* Women of child-bearing potential who are not willing to use barrier or depot contraception methods~* Use of NSAIDs or aspirin (\>3 times per week) within the past 3 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- I (Type: EXPERIMENTAL): Active treatment with AST-120

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fat Tolerance From Lipid Emulsion Infusion Packaged in Glass or Plastic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients who present to the neonatal intensive care unit at BIDMC who require intravenous nutritional support~Exclusion Criteria:~* Any patients receiving intravenous steroids

- Gender: ALL
- Minimum Age: 2 Days
- Maximum Age: 10 Days
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* Patients hospitalized in ICU~* Patients under mechanical ventilation~* Patients with an expected length of stay of at least 4 days after inclusion~* Patients identified with an MDRB digestive carriage, determined by a positive rectal swab previously performed during ICU stay, according to usual screening~* Expected antibiotic (ATB) duration \< 10 days~* Informed written consent from the patient~* In unconscious patients who are not able to give consent for inclusion in the study, relatives (next-of-kin) give assent on every patient's behalf, and patients will be later given the opportunity to withdraw from the study~Exclusion Criteria:~* Patients with a high risk of death within 5 days according to investigator's opinion, or subjected to therapeutic limitation decisions~* Antibiotherapy of more than 4 consecutive days at inclusion~* Confirmed or suspected intestinal ischemia~* Confirmed or suspected toxic megacolon or gastrointestinal perforation~* Any gastro-intestinal bleeding in the past 3 months~* Any history of abdominal surgery in the past 3 months~* Any history of chronic digestive disease or gastro-intestinal resection~* Any counter indication for Trendelenburg position~* Neutropenia (neutrophil counts \< 500 cells/µL)~* Ongoing immunosuppressive therapy (chemotherapy, any immunosuppressive agents, excluding corticosteroids \< 0,5 mg/kg/d of equivalent prednisolone)~* Enrollment in another trial that may interfere with this study~* Known allergy or intolerance to trehalose or maltodextrin and latex~* Pregnancy or breastfeeding~* Patients with EBV- serology

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- treated patients (Type: EXPERIMENTAL): Treated wit FMT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Protein Supplementation in Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~* On hemodialysis for more than 3 months, on a thrice weekly hemodialysis program.~* Adequately dialyzed (Kt/V \> 1.2).~* Age 18-75~Exclusion criteria:~* Pregnant women.~* Severe unstable underlying disease besides commonly associated with end stage renal disease. Cardiac patients that are stable will be included.~* Patients hospitalized within the last month prior to the study.~* Patients with malfunctioning arterial-venous access \[recirculation and/or blood flow \< 500 ml/min for an arterial-venous graft (AVG) or \<400 ml/min for an arterial-venous fistula (AVF)\] Patients receiving steroids and/or other immunosuppressive agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 30 ml per serving
- 2 (Type: ACTIVE_COMPARATOR): 60 ml per serving
- 3 (Type: NO_INTERVENTION): chronic hemodialysis patients
- 4 (Type: NO_INTERVENTION): healthy subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Antiplatelet for both primary and secondary prophylaxis~* Peptic ulcers of Forrest class Ia (spurting of blood), Ib (oozing of blood), IIa (visible vessel) \& IIb (adherent clot)~Exclusion Criteria:~* Peptic ulcers of class IIc (pigmented ulcer base) \& III (clean ulcer base)~* Unsuccessful endoscopic hemostasis~* Ulcer perforation~* Gastric outlet obstruction precluding passage of scope to D2~* Malignant ulcers~* Proton pump inhibitor (PPI) allergy~* Concomitant anticoagulants~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Second-look OGD group (Type: EXPERIMENTAL): Second-look OGD within 16 to 24 hours after primary OGD, in addition to standard care (esomeprazole infusion for three days, followed by oral esomeprazole.~OGD will be offered if signs of rebleeding present)
- Standard care group (Type: ACTIVE_COMPARATOR): Esomeprazole infusion for three days, followed by oral esomeprazole. OGD will be offered if signs of rebleeding present

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues